Drugmakers give surprising response to Medicare drug price offers
Wednesday, 20 March 2024, 10:00
Summary
Pharmaceutical executives have shown unexpected positivity towards initial Medicare drug price offers.
Reactions
- AstraZeneca and Pfizer hinted at encouraging responses from CMS.
- Patient groups remain cautious, suspecting potential profit-driven motives.
Legal Battles
- Judges require proof of actual harm to support challenges against Medicare negotiations.
- Industry lawsuits indicate concerns over potential impacts despite discounts projected by the Congressional Budget Office.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.